Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo).

被引：0
|
作者：
Shachar, Shlomit Strulov
Fried, Rachel
Shafran, Itamar
Moskovitz, Mor Tal
Williams, Grant Richard
Bar-Sela, Gil
Reiner-Benaim, Anat Strulov
Wollner, Mira
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
[2] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[4] Rambam Hlth Care Campus, Harduf, Israel
[5] Rambam Hlth Care Campus, Div Oncol, Haifa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21010
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
    Ali, Omar Hasan
    Diem, Stefan
    Markert, Eva
    Jochum, Wolfram
    Kerl, Katrin
    French, Lars E.
    Speiser, Daniel E.
    Fruh, Martin
    Flatz, Lukas
    OncoImmunology, 2016, 5 (11):
  • [42] Nivolumab for treating non-small cell lung cancer
    Guibert, Nicolas
    Mazieres, Julien
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1789 - 1797
  • [43] Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
    Morgensztern, Daniel
    Herbst, Roy S.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3713 - 3717
  • [44] Perioperative Nivolumab in non-small cell Lung Cancer
    Lorenz, Judith
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (18) : 1065 - 1066
  • [45] Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
    Burgos-San Jose, Amparo
    Colomer-Aguilar, Claudia
    Martinez-Caballero, Daniel
    Massuti-Sureda, Bartomeu
    FARMACIA HOSPITALARIA, 2021, 45 (03) : 121 - 125
  • [46] Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
    Lim, Joline S. J.
    Soo, Ross A.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (05) : 444 - 454
  • [47] Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient
    Karakas, Yusuf
    Yuce, Deniz
    Kilickap, Saadettin
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (10) : 621 - +
  • [48] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
    Costantini, Adrien
    Julie, Catherine
    Dumenil, Coraline
    Helias-Rodzewicz, Zofia
    Dumoulin, Jennifer
    Giraud, Violaine
    Labrune, Sylvie
    Chinet, Thierry
    Emile, Jean-Francois
    Giroux-Leprieur, Etienne
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [49] COST OF IMMUNOTHERAPY TO TREAT LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (MUC) AND METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC)
    Bilir, S. P.
    Munakata, J.
    Yim, Y. M.
    Ogale, S.
    VALUE IN HEALTH, 2017, 20 (05) : A99 - A99
  • [50] The Effect of Radiotherapy on Clinical Outcomes for Patients Receiving Immunotherapy for Metastatic Non-Small Cell Lung Carcinoma
    D'Rummo, K. A.
    Al-Jumayli, M.
    Huang, C. H.
    Wang, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E501 - E502
12345